Sandbox:Irfan: Difference between revisions
Jump to navigation
Jump to search
Irfan Dotani (talk | contribs) No edit summary |
Irfan Dotani (talk | contribs) |
||
Line 121: | Line 121: | ||
|} | |} | ||
=== | ===Borderline Personality Disorder=== | ||
* '''1 Stage 1 - Name of stage''' | * '''1 Stage 1 - Name of stage''' | ||
Line 207: | Line 207: | ||
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose) | ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose) | ||
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose) | ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose) | ||
* 1.00 '''Therapies''' | |||
** 1.10 '''Psychotherapy''' | |||
*** 1.11 Simple supportive therapy alone may enhance self-esteem and mobilize the existing strengths of individuals with BPD.<ref>Aviram, R.B.; D.J. Hellerstein, J. Gerson, et al. (May 2004). "[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15330220&dopt=Abstract Adapting supportive psychotherapy for individuals with Borderline personality disorder who self-injure or attempt suicide]". ''J Psychiatr Pract'' '''10''' (3): 145-55. Retrieved on 2007-09-23.</ref> Specific psychotherapies may involve sessions over several months or, as is particularly common for personality disorders, several years. | |||
*** 1.12 Psychotherapy can often be conducted either with individuals or with groups. Group therapy can aid the learning and practice of interpersonal skills and self-awareness by individuals with BPD<ref name=AMN>Gunderson, J.G. MD (2006-04-10). "[http://www.health.am/psy/more/borderline_personality_disorder_psychotherapies "Borderline Personality Disorder - Psychotherapies]". ''American Medical Network''. Retrieved on 2007-09-23.</ref> although drop-out rates may be problematic.<ref>Hummelen, B.; T. Wilberg, S. Karterud (January 2007). "[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17266430 Interviews of female patients with borderline personality disorder who dropped out of group psychotherapy]". ''Int J Group Psychother'' '''57''' (1): 67-91. Retrieved on 2007-09-23.</ref> | |||
** 1.20 '''Dialectical Behavioral Therapy''' | |||
*** 1.21 | |||
*** 1.22 | |||
*** 1.23 | |||
** 1.30 '''Schema Therapy''' | |||
*** | |||
*** | |||
*** | |||
** 1.40 '''Cognitive Behavioral Therapy''' | |||
*** | |||
*** | |||
*** | |||
** 1.50 '''Marital or Family Therapy''' | |||
*** | |||
*** | |||
*** | |||
** 1.60 '''Psychoanalysis''' | |||
*** | |||
*** | |||
*** | |||
** 1.70 '''Transference Focused Psychotherapy''' | |||
*** | |||
*** | |||
*** | |||
** 1.80 '''Cognitive Analytic Therapy''' | |||
*** | |||
*** | |||
*** | |||
* 2.0 '''Medication''' | |||
** 2.1 '''Antidepressants''' | |||
*** | |||
*** | |||
*** | |||
** 2.2 '''Antipsychotics''' | |||
* 3.0 '''Mental Health Services and Recovery''' | |||
** 3.1 '''Combining Pharmacotherapy and Psychotherapy''' | |||
*** | |||
*** | |||
*** | |||
** 3.2 '''Difficulties in Therapy''' | |||
*** | |||
*** | |||
*** | |||
** 3.3 '''Other Strategies''' | |||
*** | |||
*** | |||
*** |
Revision as of 15:08, 31 July 2018
Findings | Suggestive of | |||
---|---|---|---|---|
System | General Appearance | Deposition | Condensation | |
Deposition | Condensation | |||
Deposition | Condensation | |||
Vital Signs | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Skin | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Head | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Eyes | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Ears | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Nose | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Throat | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Neck | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Lungs | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Heart | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Abdomen | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Back | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Genitourinary | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Extremities | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation | |||
Neuromuscular | Deposition | Condensation | ||
Deposition | Condensation | |||
Deposition | Condensation |
Borderline Personality Disorder
- 1 Stage 1 - Name of stage
- 1.1 Specific Organ system involved 1
- 1.1.1 Adult
- Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
- Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
- Preferred regimen (3): drug name 500 mg q12h for 14-21 days
- Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
- Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
- 1.1.2 Pediatric
- 1.1.2.1 (Specific population e.g. children < 8 years of age)
- Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
- Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
- Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
- 1.1.2.2 (Specific population e.g. 'children < 8 years of age')
- Preferred regimen (1): drug name 4 mg/kg/day PO q12h(maximum, 100 mg per dose)
- Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
- 1.1.2.1 (Specific population e.g. children < 8 years of age)
- 1.1.1 Adult
- 1.2 Specific Organ system involved 2
- 1.1 Specific Organ system involved 1
- 2 Stage 2 - Name of stage
- 2.1 Specific Organ system involved 1
- Note (1):
- Note (2):
- Note (3):
- 2.1.1 Adult
- Parenteral regimen
- Oral regimen
- Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
- Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
- Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
- Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
- Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
- 2.1.2 Pediatric
- Parenteral regimen
- Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
- Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
- Alternative regimen (2): drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '(Contraindications/specific instructions)'
- Oral regimen
- Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
- Preferred regimen (2): drug name (for children aged ≥ 8 years) 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
- Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
- Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
- Parenteral regimen
- 2.2 'Other Organ system involved 2'
- Note (1):
- Note (2):
- Note (3):
- 2.2.1 Adult
- Parenteral regimen
- Oral regimen
- Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
- Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
- Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
- Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
- Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
- 2.2.2 Pediatric
- Parenteral regimen
- Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
- Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
- Alternative regimen (2): drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
- Oral regimen
- Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
- Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
- Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
- Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
- Parenteral regimen
- 2.1 Specific Organ system involved 1
- 1.00 Therapies
- 1.10 Psychotherapy
- 1.11 Simple supportive therapy alone may enhance self-esteem and mobilize the existing strengths of individuals with BPD.[1] Specific psychotherapies may involve sessions over several months or, as is particularly common for personality disorders, several years.
- 1.12 Psychotherapy can often be conducted either with individuals or with groups. Group therapy can aid the learning and practice of interpersonal skills and self-awareness by individuals with BPD[2] although drop-out rates may be problematic.[3]
- 1.20 Dialectical Behavioral Therapy
- 1.21
- 1.22
- 1.23
- 1.30 Schema Therapy
- 1.40 Cognitive Behavioral Therapy
- 1.50 Marital or Family Therapy
- 1.60 Psychoanalysis
- 1.70 Transference Focused Psychotherapy
- 1.80 Cognitive Analytic Therapy
- 1.10 Psychotherapy
- 2.0 Medication
- 2.1 Antidepressants
- 2.2 Antipsychotics
- 2.1 Antidepressants
- 3.0 Mental Health Services and Recovery
- 3.1 Combining Pharmacotherapy and Psychotherapy
- 3.2 Difficulties in Therapy
- 3.3 Other Strategies
- 3.1 Combining Pharmacotherapy and Psychotherapy
- ↑ Aviram, R.B.; D.J. Hellerstein, J. Gerson, et al. (May 2004). "Adapting supportive psychotherapy for individuals with Borderline personality disorder who self-injure or attempt suicide". J Psychiatr Pract 10 (3): 145-55. Retrieved on 2007-09-23.
- ↑ Gunderson, J.G. MD (2006-04-10). ""Borderline Personality Disorder - Psychotherapies". American Medical Network. Retrieved on 2007-09-23.
- ↑ Hummelen, B.; T. Wilberg, S. Karterud (January 2007). "Interviews of female patients with borderline personality disorder who dropped out of group psychotherapy". Int J Group Psychother 57 (1): 67-91. Retrieved on 2007-09-23.